Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 1/20 | 0.36 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.36 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.35 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | SCN10A | Q9Y5Y9 | 5/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | KIF11 | P52732 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | TYR | P14679 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2693049 | 0.84 | KMT2A (0.39) | PDE2ACACNA1IRAB9ASCN10AKIF11 | |
| SCHEMBL855236 | 0.83 | CACNA1I (0.38) | CACNA1IDGAT1ALOX5APRAB9AKDM4E | |
| SCHEMBL9987929 | 0.82 | KMT2A (0.44) | PDE2AKDM4EPOLBTSHRKIF11 | |
| SCHEMBL22630752 | 0.82 | KMT2A (0.44) | PDE2AKDM4EPOLBTSHRKIF11 | |
| SCHEMBL3074268 | 0.82 | KMT2A (0.44) | PDE2AKDM4EPOLBTSHRKIF11 | |
| SCHEMBL23122207 | 0.82 | KMT2A (0.44) | PDE2AKDM4EPOLBTSHRKIF11 | |
| Hydrochloric Acid SCHEMBL30615195 | 0.81 | KMT2A (0.43) | PDE2AKDM4EPOLBTSHRKIF11 | |
| Hydrochloric Acid SCHEMBL29106444 | 0.81 | KMT2A (0.43) | PDE2AKDM4EPOLBTSHRKIF11 | |
| Hydrochloric Acid SCHEMBL29106441 | 0.81 | KMT2A (0.43) | PDE2AKDM4EPOLBTSHRKIF11 | |
| Hydrochloric Acid SCHEMBL30049359 | 0.81 | KMT2A (0.43) | PDE2AKDM4EPOLBTSHRKIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8168668-B2 | Compounds | ASTRAZENECA AB (SE) | 2012-05-01 | — | — | US | disclosed |
| US-8168668-B2 | Compounds | ASTRAZENECA AB (SE) | 2012-05-01 | — | — | US | disclosed |
| US-8168668-B2 | Compounds | ASTRAZENECA AB (SE) | 2012-05-01 | — | — | US | disclosed |
| EP-1966156-B1 | NEW COMPOUNDS III | ASTRAZENECA AB (SE) | 2011-12-21 | — | — | EP | disclosed |
| EP-1966156-B1 | NEW COMPOUNDS III | ASTRAZENECA AB (SE) | 2011-12-21 | — | — | EP | disclosed |
| CN-101389610-B | Novel benzimidazole derivatives as vanilloid receptor 1 (vrl) inhibitors | ASTRAZENECA AB (SE) | 2011-12-07 | — | — | CN | disclosed |
| US-20100286202-A1 | New Compounds | ASTRAZENECA AB (SE) | 2010-11-11 | — | — | US | disclosed |
| US-20100286202-A1 | New Compounds | ASTRAZENECA AB (SE) | 2010-11-11 | — | — | US | disclosed |
| US-20100286202-A1 | New Compounds | ASTRAZENECA AB (SE) | 2010-11-11 | — | — | US | disclosed |
| US-7618993-B2 | Compounds | ASTRAZENECA AB (SE) | 2009-11-17 | — | — | US | disclosed |
| US-7618993-B2 | Compounds | ASTRAZENECA AB (SE) | 2009-11-17 | — | — | US | disclosed |
| US-7618993-B2 | Compounds | ASTRAZENECA AB (SE) | 2009-11-17 | — | — | US | disclosed |
| CN-101389610-A | Novel benzimidazole derivatives as vanilloid receptor 1 (vrl) inhibitors | ASTRAZENECA AB (SE) | 2009-03-18 | — | — | CN | disclosed |
| EP-1966156-A2 | NEW COMPOUNDS III | AstraZeneca AB (SE) | 2008-09-10 | — | — | EP | disclosed |
| US-20080171770-A1 | Compounds | ASTRAZENECA AB (SE) | 2008-07-17 | — | — | US | disclosed |
| US-20080171770-A1 | Compounds | ASTRAZENECA AB (SE) | 2008-07-17 | — | — | US | disclosed |
| US-20080171770-A1 | Compounds | ASTRAZENECA AB (SE) | 2008-07-17 | — | — | US | disclosed |
| WO-2007073303-A2 | NOVEL BENZIMIDAZOLE DERIVATIVES AS VANILLOID RECEPTOR 1 (VRL) INHIBITORS | ASTRAZENECA AB (SE) | 2007-06-28 | — | — | WO | disclosed |
| WO-2007073303-A2 | NOVEL BENZIMIDAZOLE DERIVATIVES AS VANILLOID RECEPTOR 1 (VRL) INHIBITORS | ASTRAZENECA AB (SE) | 2007-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286202-A1 | New Compounds | REN, PCSK9, FURIN | PDE2A 1120/4885CACNA1I 1281/4885DGAT1 863/4885 |
| US-20080171770-A1 | Compounds | REN, PCSK9, SLC10A1 | PDE2A 1313/4885CACNA1I 1129/4885DGAT1 655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.